Data completeness
5/8 — Partial
ENSPRYNG by Roche is satralizumab-mwge exerts therapeutic effects in nmosd and ted is unknown but is presumed to involve inhibition of il-6-mediated signaling through binding to soluble and membrane-bound il-6 receptors. Approved for neuromyelitis optica spectrum disorder (nmosd) in adult patients, thyroid eye disease (ted) regardless of ted activity, duration in adult patients. First approved in 2020.
Drug data last refreshed 3h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENSPRYNG (satralizumab) is a monoclonal antibody approved in August 2020 for neuromyelitis optica spectrum disorder (NMOSD). It works by targeting IL-6 signaling to reduce inflammatory attacks in this rare autoimmune neurological condition. Administered as a subcutaneous injection, it represents an important treatment option for patients with this severe disease.
$34MPart D
PeakStable
Product is at peak maturity in a niche rare disease market with ~1,600 annual Medicare claims, indicating established but limited patient base suitable for specialized field and medical affairs teams.
Mechanism of Action
satralizumab-mwge exerts therapeutic effects in NMOSD and TED is unknown but is presumed to involve inhibition of IL-6-mediated signaling through binding to soluble and membrane-bound IL-6 receptors.
Worked on ENSPRYNG at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.